{"filing":{"accession_number":"0001087294-26-000070","cik":"0001087294","ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"cpix-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000070/cpix-20261023.htm"},"events":[{"id":37688,"run_id":34733,"accession_number":"0001087294-26-000070","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cumberland announced top-line results from a Phase 2a clinical trial (ASSIST-SSc) for ifetroban in systemic sclerosis, demonstrating safety and tolerability. This is a material clinical milestone for a pharmaceutical company's drug development program, but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant development in the company's pipeline—making operational_other the most appropriate classification.","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42476,"accession_number":"0001087294-26-000070","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cumberland announced top-line results from a Phase 2a clinical trial (ASSIST-SSc) for ifetroban in systemic sclerosis, demonstrating safety and tolerability. This is a material clinical milestone for a pharmaceutical company's drug development program, but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant development in the company's pipeline—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:03:50.115888+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42476,"accession_number":"0001087294-26-000070","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cumberland announced top-line results from a Phase 2a clinical trial (ASSIST-SSc) for ifetroban in systemic sclerosis, demonstrating safety and tolerability. This is a material clinical milestone for a pharmaceutical company's drug development program, but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant development in the company's pipeline—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:03:50.115888+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-10-23"}]}